{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:47:47Z","timestamp":1792511267599,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3606600"],"award-info":[{"award-number":["2023YFC3606600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3503400"],"award-info":[{"award-number":["2023YFC3503400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["24J22800800"],"award-info":[{"award-number":["24J22800800"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","award":["21YF1401900"],"award-info":[{"award-number":["21YF1401900"]}],"id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200745"],"award-info":[{"award-number":["32200745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103087","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:51:37Z","timestamp":1791211897000},"page":"103087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging innate and adaptive immunity: A bispecific SIRP\u03b1D1-\u03b1PCSK9 fusion protein reprograms macrophages for durable tumor clearance"],"prefix":"10.1016","volume":"7","author":[{"given":"Caili","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaicheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianxin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1654-5550","authenticated-orcid":false,"given":"Xuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103087_bib1","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1016\/j.cub.2020.01.031","article-title":"Tumor-associated macrophages","volume":"30","author":"Cassetta","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.xcrm.2026.103087_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103087_bib3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRPalpha Immune Checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103087_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103087_bib5","article-title":"Targeting the CD47\/SIRPalpha pathway in malignancies: recent progress, difficulties and future perspectives","volume":"14","author":"Jiang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-025-01742-x","article-title":"HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPalpha pathway with high safety and preclinical efficacy for hematological and solid tumors","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103087_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.103087_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41568-025-00893-w","article-title":"Targeting phagocytosis checkpoints for cancer immunotherapy","volume":"26","author":"Veillette","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.103087_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRPalpha-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRPalpha signal pathway via blocking the \u201cdon't eat me\u201d signal and activating the \u201ceat me\u201d signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib12","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103087_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRPalpha axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.103087_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001408","article-title":"Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review","volume":"8","author":"Lecoultre","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.103087_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib16","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103087_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib18","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/trf.70111","article-title":"IgG4 anti-CD47: Erythrophagocytosis and potential transfusion complications","volume":"66","author":"Boligan","year":"2026","journal-title":"Transfusion"},{"key":"10.1016\/j.xcrm.2026.103087_bib19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/imj.15934","article-title":"Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody)","volume":"52","author":"Tan","year":"2022","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.xcrm.2026.103087_bib20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib21","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjae041","article-title":"Super-resolution microscopy unveils the nanoscale organization and self-limiting clustering of CD47 in human erythrocytes","volume":"16","author":"Yang","year":"2025","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.103087_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bcmd.2006.01.012","article-title":"Membrane mobility and clustering of Integrin Associated Protein (IAP, CD47)--major differences between mouse and man and implications for signaling","volume":"36","author":"Subramanian","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.xcrm.2026.103087_bib24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41591-019-0356-z","article-title":"Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPalpha axis and a target for cancer immunotherapy","volume":"25","author":"Logtenberg","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103087_bib25","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103087_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.1401719","article-title":"Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPalpha Facilitate Apoptotic Cell Clearance by Macrophages","volume":"195","author":"Lv","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1686180","article-title":"A CD47 antibody with minimized erythrocyte and thrombocyte toxicities","volume":"15","author":"Pei","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib28","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-25-1826","article-title":"A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma","volume":"31","author":"Strati","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib29","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2019-122793","article-title":"TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties","volume":"134","author":"Meng","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.103087_bib30","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.32604\/or.2025.071708","article-title":"CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge","volume":"33","author":"Guo","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib31","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.apsb.2022.12.016","article-title":"Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives","volume":"13","author":"Ye","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.103087_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027235","article-title":"Inhibition of the CD47-SIRPalpha axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data","volume":"13","author":"Son","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib33","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","article-title":"Antigen Cross-Presentation by Macrophages","volume":"11","author":"Muntjewerff","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155022","article-title":"CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity","volume":"7","author":"Modak","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2026.103087_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/1074-7613(95)90067-5","article-title":"Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages","volume":"3","author":"Norbury","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103087_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13045-020-00989-w","article-title":"Targeting the myeloid checkpoint receptor SIRPalpha potentiates innate and adaptive immune responses to promote anti-tumor activity","volume":"13","author":"Kuo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70014","article-title":"Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8(+) T cells","volume":"13","author":"Christo","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39858","article-title":"IMM2520, a novel anti-CD47\/PD-L1 bispecific antibody for cancer immune therapy","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.xcrm.2026.103087_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/imt-2022-0087","article-title":"Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma","volume":"15","author":"Nan","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.xcrm.2026.103087_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrendo.2012.254","article-title":"Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels","volume":"9","author":"Betteridge","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103087_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103087_bib42","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","article-title":"The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Imbalzano","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.xcrm.2026.103087_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103087_bib44","article-title":"Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8(+) T cells and the exclusion of Treg cells","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib45","first-page":"488","article-title":"Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1\/PD-L1 Immunotherapy","volume":"7","author":"Sun","year":"2024","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.xcrm.2026.103087_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.103087_bib47","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","article-title":"Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPalpha, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study","volume":"17","author":"Yang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103087_bib49","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3324\/haematol.2024.286208","article-title":"Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study","volume":"110","author":"Kim","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.103087_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRPalpha as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.103087_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRPalpha blocking-based immunotherapy: Current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103087_bib53","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRP\u03b1 requires Fc-Fc\u03b3R interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.103087_bib54","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","article-title":"The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions","volume":"41","author":"Osorio","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103087_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib56","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.103087_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, Mechanisms, and Significance of Macrophage Plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.xcrm.2026.103087_bib58","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/08820139.2022.2027439","article-title":"PCSK9 Suppresses M2-Like Tumor-Associated Macrophage Polarization by Regulating the Secretion of OX40L from Hepatocellular Carcinoma Cells","volume":"51","author":"Hu","year":"2022","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.xcrm.2026.103087_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","article-title":"PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:13:35Z","timestamp":1792509215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126005045"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103087","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging innate and adaptive immunity: A bispecific SIRP\u03b1D1-\u03b1PCSK9 fusion protein reprograms macrophages for durable tumor clearance","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103087"}}